Skip to main content

Breast Cancer Translational Research Laboratory J.C. Heuson

Description

The aim of the Institut Bordet J.-C. Heuson Breast Cancer Translational Research Laboratory (BCTL) is to facilitate the transfer of scientific discoveries about breast cancer that are made in the laboratory into clinical practice. It seeks to improve the molecular characterisation of breast cancer through the use of leading-edge technologies. A particular objective is to improve understanding of the biology of these cancers and of the mechanisms involved in resistance to treatment.

Research Projects

The various projects of the laboratory are funded by : Les Amis de l’Institut Bordet, FNRS, FNRS-Télévie, Fondation contre le Cancer, Breast Cancer Research Fondation (BCRF), Fonds Julie et Françoise Drion.

Project 1

Characterization of endocrine resistant Luminal Breast Cancer using spatial transcriptomics AND epigenetic Analysis 
  • Project leader(s) : Christos Sotiriou, Françoise Rothé and Mattia Rediti
  • Collaborations : 
    • Dr François Fuks, Laboratory of Cancer Epigenetics, ULB-Cancer Research Center (U-CRC), Université libre de Bruxelles
    •  Prof Lundeberg at the SciLife laboratory, Stockholm, Sweden
    • Dr Frédérick Libert, ULB/VUB Brightcore sequencing facility

Project 2

Molecular characterization of triple-negative breast cancer using spatial transcriptomics and single cell analysis.
  • Project leader(s) : Christos Sotiriou, Françoise Rothé
  • Collaborations : 
    • Prof. Lundeberg at the SciLife laboratory (Stockholm, Sweden)
    • Dr Frédérick Libert, ULB/VUB Brightcore sequencing facility

Project 3

Tracking tumor evolution and distant recurrence in breast cancer by modeling tumor dormancy and the molecular clock rate

Project 4

Uncovering the immune landscape of breast cancer 

Project 5

INTERROGATING THE FUNCTIONAL RELEVANCE OF A-TO-I RNA EDITING IN BREAST CANCER

Our team

Head of BCTL
Prof Christos Sotiriou, MD PhD

Associate head
Françoise Rothé, PhD

Translational research manager
Marion Maetens, PhD

Scientists
David Venet, PhD
Laurence Buisseret, MD PhD
Danai Fimereli , PhD

PhD students
Floriane Dupont
Yacine Bareche
Mattia Rediti
Xiaoxiao Wang

Lab technicians
Ghizlane Rouas
Samira Majjaj
Delphine Vincent

Administrative assistant
Julie Noël

 Scientific publications

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Authors : Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E, Ignatiadis M
Year : 2019
Journal : Cancer
Volume : 125
Pages : 307-316

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer.

Authors : Lan Q, Peyvandi S, Duffey N, Huang YT, Barras D, Held W, Richard F, Delorenzi M, Sotiriou C, Desmedt C, Lorusso G, Rüegg C
Year : 2019
Journal : Oncogene
Volume : 38
Pages : 2814-2829

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Authors : Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S
Year : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 559-569

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Authors : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, Von Minckwitz G, Baselga J
Year : 2019
Journal : Ann Oncol

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Authors : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Year : 2019
Journal : Ann Oncol

Follow us!

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more